We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Infectious Diseases

Infectious Diseases

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Cultural Diversity in ICU: A Protective Factor Against Sepsis Mortality
Critical Caređa dạng văn hóahealth disparities

Cultural Diversity in ICU: A Protective Factor Against Sepsis Mortality

By MedXY|Apr 24, 2026

A multicenter study reveals that culturally and linguistically diverse patients with sepsis had lower in-hospital mortality and shorter ICU stays compared to non-CaLD patients, challenging prior assumptions about healthcare disparities.

Combination Antiviral Therapy Improves Survival in HHV-6B Encephalitis Post-Cord Blood Transplant
Infectious Diseasescord blood transplantationsurvival outcomes

Combination Antiviral Therapy Improves Survival in HHV-6B Encephalitis Post-Cord Blood Transplant

By MedXY|Apr 24, 2026

A real-world study reveals FCN/GCV combination therapy enhances 1-year survival in HHV-6B encephalitis post-CBT, particularly after neutrophil engraftment, compared to monotherapy. Findings underscore the need for tailored antiviral strateg

Antifungal Therapy Slashes Mortality in COVID-19-Associated Pulmonary Aspergillosis: European Data Confirms
Critical Careantifungal treatmentCAPA

Antifungal Therapy Slashes Mortality in COVID-19-Associated Pulmonary Aspergillosis: European Data Confirms

By MedXY|Apr 23, 2026

A multicenter European cohort study demonstrates that antifungal treatment significantly reduces 60-day mortality in COVID-19-associated pulmonary aspergillosis (CAPA), particularly in immunocompromised patients. Key findings underscore the

Nine-Valent HPV Vaccine Cuts Cancer Risk Nearly in Half for Males: Landmark Study Supports Sex-Neutral Immunization
Infectious Diseasescancer preventionHPV vaccine

Nine-Valent HPV Vaccine Cuts Cancer Risk Nearly in Half for Males: Landmark Study Supports Sex-Neutral Immunization

By MedXY|Apr 15, 2026

A large-scale retrospective cohort study demonstrates that 9-valent HPV vaccination in males aged 9-26 years is associated with a 46% reduction in HPV-related cancer risk. The findings support sex-neutral HPV vaccination strategies and high

WBC SPECT/CT Outperforms MRI in Early Detection of Diabetic Foot Osteomyelitis, Study Finds
Infectious Diseasesbone biopsydiabetic foot osteomyelitis

WBC SPECT/CT Outperforms MRI in Early Detection of Diabetic Foot Osteomyelitis, Study Finds

By MedXY|Apr 13, 2026

A prospective study of 47 patients reveals that white blood cell SPECT/CT demonstrates superior sensitivity and specificity compared to conventional MRI for initial diagnosis of diabetic foot osteomyelitis. While both modalities perform equ

Why Hepatitis E Remains a Silent Threat in Transplant Recipients: Key Insights from Two Decades of Data
GastroenterologyimmunosuppressionLiệu pháp ribavirin

Why Hepatitis E Remains a Silent Threat in Transplant Recipients: Key Insights from Two Decades of Data

By MedXY|Apr 6, 2026

A 20-year retrospective study of 6,452 solid organ transplant patients reveals hepatitis E infection rates of 3.5%, with chronicity rates exceeding 65%. The findings highlight the critical importance of HEV screening and the effectiveness o

Fluvoxamine Shows Promise for Treating Long COVID Fatigue: Results from Adaptive Randomized Trial
Infectious Diseasesfatiguefluvoxamine

Fluvoxamine Shows Promise for Treating Long COVID Fatigue: Results from Adaptive Randomized Trial

By MedXY|Apr 3, 2026

A randomized trial of 399 adults with long COVID fatigue found that fluvoxamine significantly reduced fatigue severity at 60 and 90 days compared to placebo, while metformin showed no benefit. The study represents a potential breakthrough i

Hidden Triggers: Recent Infections Linked to a 2.6-Fold Increase in Cryptogenic Stroke Risk in Young Adults
Infectious DiseasesCoagulation Biomarkersinfectious diseases

Hidden Triggers: Recent Infections Linked to a 2.6-Fold Increase in Cryptogenic Stroke Risk in Young Adults

By MedXY|Mar 30, 2026

The SECRETO study reveals that infections within the preceding week significantly increase the risk of cryptogenic ischemic stroke in patients aged 18–49, with elevated von Willebrand Factor and Factor VIII levels serving as critical biomar

Tuberculosis Post-Allogeneic Hematopoietic Stem Cell Transplantation in Low-Incidence Settings: Risk Factors, Clinical Trajectories, and Screening Mandates
Clinical UpdatesAllo-HSCTepidemiology

Tuberculosis Post-Allogeneic Hematopoietic Stem Cell Transplantation in Low-Incidence Settings: Risk Factors, Clinical Trajectories, and Screening Mandates

By MedXY|Apr 2, 2026

This review analyzes a decade-long nationwide study on TB after Allo-HSCT in France, revealing a 60/100,000 incidence rate, high extrapulmonary involvement, and the critical need for screening patients from high-incidence regions.

Distinct Biological Pathways Drive Restrictive and Obstructive Post-Tuberculosis Lung Disease: Insights from a Kenyan Cohort
Infectious Diseasesinfectious diseasesPost-Tuberculosis Lung Disease

Distinct Biological Pathways Drive Restrictive and Obstructive Post-Tuberculosis Lung Disease: Insights from a Kenyan Cohort

By MedXY|Mar 24, 2026

A prospective Kenyan cohort study identifies that post-tuberculosis lung disease (PTLD) affects 50% of survivors, driven by divergent transcriptomic signatures: early pro-fibrotic inflammation in restrictive phenotypes and persistent interf

Predicting Post-Discharge Survival: The Long-term Pneumonia Mortality Index (L-PMI) Sets a New Standard for CAP Prognosis
Infectious Diseasescommunity-acquired pneumoniaL-PMI

Predicting Post-Discharge Survival: The Long-term Pneumonia Mortality Index (L-PMI) Sets a New Standard for CAP Prognosis

By MedXY|Mar 19, 2026

Researchers have developed and validated the Long-term Pneumonia Mortality Index (L-PMI), a clinical tool that accurately predicts mortality up to one year following hospital discharge for community-acquired pneumonia, including COVID-19 ca

Recent Infections Act as a Transient Trigger for Cryptogenic Stroke in Young Adults via Thromboinflammatory Pathways
Infectious Diseasesinfectious diseasesThromboinflammation

Recent Infections Act as a Transient Trigger for Cryptogenic Stroke in Young Adults via Thromboinflammatory Pathways

By MedXY|Mar 18, 2026

The SECRETO study demonstrates that infections within the preceding week increase the odds of cryptogenic ischemic stroke by 2.6-fold in young adults, primarily driven by transient increases in von Willebrand Factor and Factor VIII levels.

Tuberculosis Post-Allogeneic Hematopoietic Stem Cell Transplantation: Insights from a Decade-Long Nationwide Study in a Low-Incidence Setting
Clinical UpdatesAllo-HSCTinfectious disease

Tuberculosis Post-Allogeneic Hematopoietic Stem Cell Transplantation: Insights from a Decade-Long Nationwide Study in a Low-Incidence Setting

By MedXY|Mar 18, 2026

This nationwide retrospective study in France highlights the rare but severe incidence of tuberculosis (TB) in Allo-HSCT recipients, identifying birth in high-prevalence countries as a primary risk factor and emphasizing the need for target

Metformin and Ursodeoxycholic Acid Fail to Improve Post-COVID Recovery: Insights from a Randomized Controlled Trial
Infectious Diseaseslong COVIDmetformin

Metformin and Ursodeoxycholic Acid Fail to Improve Post-COVID Recovery: Insights from a Randomized Controlled Trial

By MedXY|Mar 13, 2026

A randomized clinical trial indicates that neither metformin nor ursodeoxycholic acid (UDCA) significantly improves recovery from postacute sequelae of SARS-CoV-2 (PASC) compared to placebo, highlighting the ongoing challenge of finding eff

Potent Inhibition of Hepatitis E Virus Replication by Bemnifosbuvir: Preclinical Evidence and Clinical Prospects
Clinical UpdatesViêm gan EViêm gan mãn tính

Potent Inhibition of Hepatitis E Virus Replication by Bemnifosbuvir: Preclinical Evidence and Clinical Prospects

By MedXY|Mar 8, 2026

Preclinical studies demonstrate that the nucleotide analogue bemnifosbuvir effectively suppresses Hepatitis E virus (HEV) replication, showing synergistic potential with ribavirin and a high genetic barrier to resistance.

High Effectiveness and Rare Safety Risks: Real-World Meta-Analysis Validates RSV Vaccination for Older Adults
Infectious Diseasesgeriatricspublic health

High Effectiveness and Rare Safety Risks: Real-World Meta-Analysis Validates RSV Vaccination for Older Adults

By MedXY|Mar 4, 2026

A comprehensive meta-analysis of 121.8 million individuals confirms that RSV vaccines are approximately 75% effective against hospitalization and severe disease in older adults, despite low global uptake and a rare risk of Guillain-Barré sy

Daily Chlorhexidine Bathing in the ICU: Re-evaluating Infection Prevention and Antimicrobial Stewardship through the CLEAN-IT Trial
Clinical Updatesantimicrobial stewardshipICU

Daily Chlorhexidine Bathing in the ICU: Re-evaluating Infection Prevention and Antimicrobial Stewardship through the CLEAN-IT Trial

By MedXY|Mar 3, 2026

This review synthesizes findings from the CLEAN-IT trial and historical data to evaluate the impact of chlorhexidine bathing on nosocomial infections, MDR pathogens, and reserve antibiotic consumption in critically ill patients.

Daily Chlorhexidine Bathing in the ICU: Results from the CLEAN-IT Multicentre Trial
Critical CareAntimicrobial Resistancecritical care

Daily Chlorhexidine Bathing in the ICU: Results from the CLEAN-IT Multicentre Trial

By MedXY|Mar 2, 2026

A large-scale trial in Brazilian ICUs found that daily chlorhexidine bathing did not lower overall nosocomial infection rates but significantly reduced multi-drug resistant pathogen isolation and the use of high-priority reserve antibiotics

Clinical UpdatesmpoxMVA-BNワクチン

Long-term Immunological and Clinical Outcomes of Monkeypox Virus Infection versus MVA-BN Vaccination: A 24-Month Longitudinal Cohort Analysis

By MedXY|Mar 2, 2026

This 24-month Belgian cohort study demonstrates that natural MPXV infection induces more durable and robust immunity than MVA-BN vaccination. While clinical symptoms mostly resolve within a year, persistent scarring remains common, and vacc

Fractional Yellow Fever Vaccination Fails Non-Inferiority in Infants: Why Adult Data Cannot Be Extrapolated to Pediatric Populations
Infectious Diseasesglobal healthPediatrics

Fractional Yellow Fever Vaccination Fails Non-Inferiority in Infants: Why Adult Data Cannot Be Extrapolated to Pediatric Populations

By MedXY|Mar 2, 2026

A randomized, double-blind trial in Kenya and Uganda reveals that a 500 IU fractional dose of yellow fever vaccine is not non-inferior to the standard dose in infants, suggesting that lower dose requirements in adults are not generalizable

Prev
5 / 17
1…34567…17
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure

Browse by specialty

Open language-specific specialty feeds and department pages.

news6829 articlesCardiology1403 articlesClinical Updates1315 articlesOncology1176 articlesDiabetes & Endocrinology868 articlesNeurology834 articlesPublic Health605 articlesGastroenterology586 articles
Hematology-Oncology
513 articles
Pediatrics493 articles
Internal Medicine464 articles